Cardiol Therapeutics ($CRDL) Stock Hub: $150M Preliminary Shelf and Expanded Program Disclosure • Updated Sep 11, 2026

01 Q2 filing refresh: cash runway holds, MAVERIC enrollment is not yet complete

The latest material corporate disclosure is Cardiol’s August 12, 2026 Form 6-K package for the quarter ended June 30. It replaces the earlier analyst estimate with filed IFRS results: C$26.08 million of cash, a C$6.08 million Q2 net loss or C$0.05 per share, and C$4.38 million of derived Q2 operating cash use. Management continues to state that available capital can fund operations and capital milestones into Q4 2027.

The clinical timeline also became more precise. The Q2 MD&A says MAVERIC had reached 75% enrollment in April and now anticipates target enrollment by the end of Q3 2026. That is a target, not a completed milestone. The company’s June corporate presentation continues to guide to Q1 2027 topline results; the Q2 filing does not restate or withdraw that readout window.

Primary documents: August 12 Form 6-K, Q2 financial statements and Q2 MD&A.

02 The short answer

CRDL is primarily a Phase III recurrent-pericarditis story. The decisive question is whether oral CardiolRx can prevent recurrence after patients stop long-term IL-1 blockade in the randomized, double-blind, placebo-controlled MAVERIC trial. A positive result could support an FDA filing and create an oral, non-immunosuppressive option in a market validated by injectable rilonacept. A negative or ambiguous result would leave Cardiol with a completed myocarditis Phase II study that missed both co-primary endpoints and a subcutaneous candidate that remains in IND-enabling development.

The August financial refresh improves visibility but does not remove financing risk. Cash was C$26.08 million at June 30; the company says this supports operations and capital milestones into Q4 2027, beyond the guided Q1 2027 readout. That runway is a management forecast, not cash divided mechanically by one quarter’s expense. The Q2 cash statement was better than Q1, but commercialization, an NDA process and any further trials would still require additional capital or a partner.

What the profile is: a single-asset clinical story whose value moves on individual trial events, with no operating revenue and a cash position the company itself frames as a plan. The open-label Phase II signal is credible enough to justify the pivotal study; it is not evidence that approval or commercial success is the most likely outcome.

03 What changed in the August 12 Q2 refresh

Actual results replaced estimates

Cardiol reported a C$6.08 million Q2 net loss, or C$0.05 per share, R&D expense of C$3.20 million and G&A expense of C$4.74 million. Because the company reports under Canadian IFRS and in Canadian dollars, the filed loss should not be compared mechanically with an earlier U.S.-market analyst EPS estimate.

Cash use slowed from Q1

First-half operating cash use was C$11.90 million. Subtracting the C$7.52 million reported for Q1 produces C$4.38 million of Q2 operating cash use. This is a Merlintrader derivation from two primary statements, not a company-labelled quarterly metric.

Enrollment timing is now explicit

The Q2 MD&A anticipates target MAVERIC enrollment by the end of Q3 2026. The milestone was therefore not complete at the filing date. The guidance narrows execution risk relative to vague “approaching completion” language, but it does not eliminate recruitment or readout-delay risk.

The capital-structure baseline moved

Issued common shares reached 116.82 million as of August 11. Listed options, warrants, RSUs, PSUs and contingent shares add 20.07 million potential equivalents, taking the maximum listed count to about 136.89 million before any future financing.

Sources: Q2 financial statements, Q2 MD&A and Q1 financial statements.

04 Why CRDL matters now

Cardiol has one program capable of defining the equity within months. MAVERIC is a pivotal, approximately 110-patient Phase III trial in recurrent pericarditis after withdrawal of long-term IL-1 blockade. The company had reached 75% enrollment in April 2026, now targets completion by the end of Q3, and continues to show Q1 2027 topline guidance in its June corporate presentation.

The evidence entering that readout is coherent but not conclusive. MAvERIC-Pilot linked improvement in pain, C-reactive protein and recurrence burden, and the full dataset is peer reviewed. Yet it enrolled only 27 patients, was open label and had no randomized control. MAVERIC exists precisely because the size of the treatment effect cannot be established from the pilot.

What improved

Q2 filing visibility; a defined end-Q3 enrollment target; peer-reviewed pericarditis data; C$26.08 million of cash; and stated runway into Q4 2027.

What must be proven

CardiolRx must separate from placebo on freedom from recurrence at 24 weeks, with a clinically meaningful effect, acceptable safety, credible handling of missing data and secondary endpoints that support rather than contradict the primary result.

What can break the story

Enrollment or readout delay, a failed or clinically weak primary result, tolerability or drug-interaction concerns, a restrictive FDA interpretation, CMC problems, or financing on unfavorable terms.

Timeline sources: Q2 MD&A and July 2026 corporate presentation.

05 Company profile and pipeline

Cardiol Therapeutics is a Canadian clinical-stage life-sciences company founded in 2017 and headquartered in Ontario. Its common shares trade on Nasdaq and the Toronto Stock Exchange under CRDL. The strategy centers on pharmaceutically manufactured cannabidiol formulations intended to modulate inflammatory and fibrotic pathways in heart disease.

Cardiol should not be analyzed as a consumer-cannabis company. CardiolRx is a chemically synthesized, high-concentration oral drug product manufactured under pharmaceutical standards. The relevant question is whether the specific formulation and dose produce reproducible efficacy and acceptable safety in a defined cardiovascular population.

The company relies on CROs, specialist clinical sites, external manufacturers and research collaborators. That asset-light model limits fixed infrastructure but adds vendor, supply, quality and timing dependencies. A successful pivotal program would still require a commercial build-out or a partner with cardiovascular market access.

Sources: company pipeline and Q2 2026 MD&A.

06 CardiolRx science: plausible mechanism, broad biology, high proof burden

CardiolRx is designed to attenuate multiple inflammatory signaling pathways, including activation of the NLRP3 inflammasome. NLRP3 is part of the innate immune system and can promote production of inflammatory cytokines, including interleukin-1 beta. Persistent activation is implicated in the inflammatory cycle of pericarditis and in inflammatory and fibrotic remodeling across several cardiac conditions.

The therapeutic idea is attractive because it targets inflammation upstream while avoiding direct immune suppression. Cardiol describes CardiolRx as non-immunosuppressive, and the product is oral rather than injectable. Those features could matter commercially if efficacy is strong enough: chronic injections, infection monitoring, cost and dependency on biologic therapy are meaningful burdens in recurrent pericarditis.

But mechanistic breadth is not automatically an advantage. A drug that modulates several pathways may produce a useful network effect, yet it can also make dose-response, exposure-response and causal interpretation more difficult. Cannabidiol has pleiotropic pharmacology, and oral exposure can be affected by formulation, food, metabolism and drug interactions. For an investment thesis, mechanism should therefore be treated as supportive—not as proof of clinical efficacy.

The decisive evidence hierarchy: plausible NLRP3 biology < biomarker and imaging signal < controlled clinical benefit < replicated pivotal benefit < approval and real-world adoption. CRDL has moved beyond the first two steps in pericarditis, but it has not yet completed the fourth.

Why the oral profile could matter

• Convenience: oral treatment could be easier to initiate and maintain than a weekly biologic injection.
• Positioning: an acceptable safety profile may support use before, after or around biologic therapy, depending on the final evidence and label.
• Access: small-molecule manufacturing and distribution may ultimately support a broader treated population, although pricing and reimbursement are not yet known.
• Differentiation risk: convenience will not compensate for materially weaker recurrence prevention than IL-1 blockade.

Mechanism and product characteristics: Cardiol pipeline page and July 2026 presentation.

07 Recurrent pericarditis: a validated market with an unfinished treatment pathway

Pericarditis is inflammation of the sac surrounding the heart. Symptoms can include sharp chest pain, breathlessness and fatigue, and repeated episodes can produce emergency visits, hospitalization, reduced activity and prolonged dependence on anti-inflammatory therapy. Cardiol estimates that about 40,000 U.S. patients experience at least one recurrence annually, while the broader U.S. prevalence of pericarditis is substantially larger.

The treatment ladder has changed. Aspirin or an NSAID plus colchicine remains the usual first-line approach for acute disease and first recurrence. The 2025 American College of Cardiology guidance moved anti-IL-1 therapy—rilonacept or anakinra—forward for patients with an inflammatory phenotype who do not respond to first-line treatment, while corticosteroids are generally handled more cautiously because of adverse effects and recurrence concerns.

Rilonacept, sold as ARCALYST, is the first and only FDA-approved therapy specifically indicated for recurrent pericarditis and reduction of recurrence risk in patients aged 12 years and older. Its Phase III RHAPSODY study produced a powerful efficacy benchmark: during randomized withdrawal, recurrence occurred in 2 of 30 patients continuing rilonacept versus 23 of 31 receiving placebo. The success of ARCALYST validates both the biology and commercial willingness to pay, but it raises the efficacy bar for new entrants.

For Cardiol, the most important commercial nuance is where CardiolRx would sit. The Phase III MAVERIC population is stable on an IL-1 blocker for at least 12 months and scheduled to discontinue it. That design directly tests whether CardiolRx can prevent relapse during a known high-risk transition. A clean win could create a valuable post-biologic pathway. It does not automatically prove first-line or broad earlier-line use. Label scope, physician comfort, comparative efficacy, drug interactions, duration of therapy and payer policy would determine how much of the headline market becomes addressable.

Treatment references: ACC 2025 concise guidance summary; FDA ARCALYST approval notice; FDA label.

08 MAvERIC-Pilot Phase II: encouraging signal, important limitations

MAvERIC-Pilot enrolled 27 adults with symptomatic recurrent pericarditis at eight U.S. centers. It was prospective and open label, not a randomized placebo-controlled efficacy trial. Patients received CardiolRx during an eight-week treatment period; 24 entered an 18-week extension in which background medications were withdrawn while CardiolRx continued.

Pain, CRP and recurrence burden moved in a consistent direction, and peer review improves transparency. The right interpretation is still signal generation: small open-label studies can overstate effect size through regression to the mean, changing background therapy, expectation and extension-selection effects. The randomized Phase III result carries the proof burden.

Primary sources: JAHA peer-reviewed article, ClinicalTrials.gov NCT05494788 and Q2 MD&A summary.

09 MAVERIC Phase III: the trial that decides the story

MAVERIC (NCT06708299) is a multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 110 adults at sites in the United States, Canada and Europe — the protocol allowed up to 25, and the registry listed 27 when read on September 2, 2026. Participants have stable recurrent pericarditis, minimal baseline pain, at least 12 months of IL-1 blocker therapy and a planned discontinuation. CardiolRx or placebo begins 10–16 days before the final scheduled IL-1 dose and continues for 24 weeks.

The primary endpoint is freedom from a new recurrent-pericarditis episode at week 24. Secondary measures include the proportion of days with no or minimal pain, pain-score changes and C-reactive protein. Cardiol says the design followed an end-of-Phase II FDA meeting and believes a successful study may support an NDA. This is useful regulatory alignment, not pre-approval or a guarantee that every positive-looking outcome will be filing-ready.

Operating timeline

The two timing statements above are both the company’s and they do not say the same thing. The corporate presentations of June and July 2026 state an expectation of topline results in the first quarter of 2027. The Outlook section of the MD&A dated August 11, 2026 says only that within the next twelve to eighteen months Cardiol expects to complete the pivotal trial and report results, which reaches into the second half of 2027 and beyond. The same wording appeared in the first-quarter MD&A, so this is not a change of language in response to anything. The reasonable reading is that Q1 2027 is the company’s working expectation while the filing keeps the wider window, and that target enrollment by the end of the third quarter of 2026 is the checkpoint that will tell a reader which of the two is holding.

Why the design is stronger than the pilot

Randomization, blinding, placebo control and a clinically meaningful recurrence endpoint address the pilot’s central limitations. Withdrawal after long-term IL-1 treatment also enriches for a high-event population, which can improve statistical power if placebo recurrences occur as expected.

What a strong readout needs

• A statistically significant and clinically meaningful difference in recurrence-free patients at 24 weeks.
• Effect size and confidence intervals that remain persuasive after inspecting event definitions, missing data and discontinuations.
• Consistency across time to recurrence, pain, CRP and clinically relevant subgroups.
• A chronic-use safety profile without a hepatic, neurological, cardiac or drug-interaction imbalance that changes benefit-risk.
• FDA feedback and CMC readiness consistent with the company’s proposed NDA path.

What could make the result ambiguous

A lower-than-expected placebo event rate, geographic heterogeneity, protocol deviations or a narrowly missed primary endpoint with favorable secondaries could produce a scientifically interesting but commercially and regulatorily uncertain outcome. ARCHER is the cautionary precedent: supportive biology does not repair a missed primary endpoint.

Sources: ClinicalTrials.gov NCT06708299, Q2 MD&A enrollment guidance and July 2026 corporate presentation.

10 ARCHER in acute myocarditis: read the endpoints, not the adjectives

ARCHER randomized 109 patients with acute myocarditis to CardiolRx or placebo for 12 weeks; 56 received active treatment and 53 placebo, and all completed the study. The modified intention-to-treat CMR analysis included 49 and 50 patients, respectively, after diagnostic confirmation.

CardiolRx was described as safe and well tolerated over 12 weeks, but the paper still deserves a granular read: diarrhea occurred in 32.1% of active patients versus 20.8% on placebo, nausea in 8.9% versus 3.8%, and increased ALT in 8.9% versus 5.7%. These data do not establish a prohibitive safety signal, but “well tolerated” does not mean adverse events were identical.

The balanced conclusion is that ARCHER produced evidence of biological and structural activity while failing both co-primary endpoints. Cardiol is reviewing next steps with experts, regulators and potential partners; it has not disclosed a new registrational study or timeline. ARCHER can support platform credibility and optionality, but it is not a near-term approval asset.

Primary sources: ESC Heart Failure publication and ClinicalTrials.gov NCT05180240.

11 CRD-38: meaningful optionality, not yet a valuation anchor

CRD-38 is a proprietary subcutaneous cannabidiol formulation for inflammatory heart disease, including heart failure. The formulation aims to improve pharmacokinetics relative to oral delivery, handle a high concentration of a lipophilic active ingredient at low viscosity and potentially support lower or less frequent dosing.

Preclinical models have shown directional improvements in cardiac function and reductions in hypertrophy, fibrosis, inflammation and adverse remodeling. The current program is formulation optimization plus IND-enabling pharmacology and toxicology. Cardiol now anticipates completion of IND-enabling studies in H1 2027 and budgets approximately C$4 million to complete them.

The Q2 use-of-funds disclosure shows C$1.40 million of first-half spending on the CRD-38 clinical program versus a C$3.40 million plan, and no spending yet on the separately planned Phase I study. This confirms that CRD-38 is not in humans and that there is no firm first-patient date in the latest filing.

For valuation, CRD-38 remains an option. IND clearance, a disclosed first-in-human protocol, practical human PK, indication selection and external capital would upgrade the asset. A favorable Phase I study would establish exposure and tolerability, not heart-failure efficacy; large peak-sales assumptions before human data create false precision.

Sources: Q2 2026 MD&A and company pipeline.

12 Regulatory path, orphan status and intellectual property

Orphan status helps, but does not validate efficacy

FDA has granted CardiolRx Orphan Drug Designation for pericarditis, including recurrent pericarditis. The designation can provide development incentives and, if approval requirements are met, potential market exclusivity. It does not mean the drug is approved, safe or effective, and exclusivity depends on the final indication and label.

End-of-Phase II alignment reduces design risk

Cardiol says MAVERIC was designed with FDA input after an end-of-Phase-II meeting and believes a successful study may support an NDA. This reduces the risk of running an obviously unacceptable pivotal design; it does not remove statistical, execution, CMC or review risk, nor prevent FDA from requesting additional analyses or evidence.

U.S. patent allowance extends the planned protection horizon

The company has described U.S. patent allowance for cannabidiol compositions used in several cardiac conditions, with expected protection into late 2040 after issuance. Allowance and a stated term are not guarantees of validity, enforceability, freedom to operate or commercial exclusivity. Patent value should therefore be treated as strategic protection, not clinical evidence or an approval substitute.

Current reference: Q2 2026 MD&A.

13 Competitive landscape: CardiolRx needs a place, not merely a market

Cardiol’s most persuasive differentiation is not “CBD for the heart.” It is the potential for a well-tolerated oral therapy to maintain remission as patients discontinue expensive chronic biologic treatment. If MAVERIC succeeds, the initial commercial message may be a bridge or maintenance strategy after IL-1 blockade. Broader earlier-line use would probably require additional evidence, physician experience or post-approval studies.

The incumbent’s commercial performance proves that recurrent pericarditis can support a substantial specialty market. After first-quarter results, Kiniksa raised its 2026 ARCALYST net-product-revenue guidance to $930–945 million; recurrent pericarditis is the franchise’s principal growth engine. Cardiol’s own presentation frames an opportunity above $1 billion. That comparison is informative but not a direct sales forecast for CardiolRx: pricing, line of therapy, duration, label breadth and efficacy could be materially different.

Sources: FDA rilonacept approval; RHAPSODY trial record; Kiniksa Q1 2026 release; Cardiol July 2026 market framing.

14 Cash, burn rate and dilution: funded through the readout, not dilution-free

10 September 2026 update: Cardiol filed a preliminary base shelf prospectus and a corresponding Form F-10 on September 10. Subject to the final prospectus receipt and U.S. effectiveness, it would allow up to US$150 million of securities over 25 months. No securities are being offered with this announcement. The company also expanded program-cost and expense disclosures following an OSC staff review. Sources and implications.

Cardiol ended June 2026 with C$26.08 million of cash and equivalents, C$29.23 million of current assets and C$5.26 million of current liabilities, including a C$1.47 million derivative liability. Working capital was C$23.96 million, or C$25.44 million excluding that non-cash derivative liability. Management says capital is sufficient for operations and planned milestones into Q4 2027.

Cash fell by only C$1.59 million from March 31 to June 30 because operating use was partly offset by roughly C$2.48 million of Q2 net financing cash and foreign-exchange effects. The lower derived Q2 operating use makes the Q4 2027 runway statement more internally plausible than a straight-line Q1 calculation, but a single quarter does not establish a stable burn rate. Contractual obligations totaled C$5.95 million, with C$5.25 million due within one year; there were no disclosed capital-expenditure commitments.

Eight quarters of losses, and what moves them

The quarterly table in the MD&A is the least glamorous disclosure in the filing and one of the more useful. It shows that the C$6.08 million loss of the second quarter is the smallest of the last eight, and that the C$10.82 million of the first quarter of 2026 was the largest. Both movements are partly mechanical: the derivative liability is revalued each quarter, adding C$1.15 million to the second quarter and C$1.53 million to the first as a credit against the loss.

The arithmetic of the second quarter closes exactly. General and administrative costs of C$4,741,864 plus research and development of C$3,196,057 give C$7,937,921 of costs. Against that sit the C$1,153,088 derivative revaluation, a C$300,668 foreign-exchange gain, C$201,332 of interest income and C$201,006 of other income, for C$1,856,094 of offsets. The difference is the C$6,081,827 reported loss. Two of those four offsets, the derivative and the exchange gain, are not operating items and would not recur in the same direction if the Canadian dollar moved the other way.

What the January raise was earmarked for, and what has been spent

The offering document of January 16, 2026 set out how the money would be used, and the Q2 MD&A reports the spending against it for the first half. Of C$33.86 million allocated, C$17.70 million had gone by June 30, or 52%. Completing the Phase III MAVERIC trial carried a C$10.00 million line, of which C$4.00 million has been spent; advancing CRD-38 toward a clinical programme carried C$3.40 million, of which C$1.40 million; the Phase 1 study of CRD-38 carried C$3.00 million and had drawn nothing.

The line worth noticing is the fourth: C$17.46 million for general and administrative costs, working capital and other research, the largest single allocation in the plan, of which C$12.30 million has been used. Separately, C$9.50 million of the October 2024 offering proceeds had gone to the clinical development of CardiolRx for recurrent pericarditis as of June 30.

Capital structure: basic count versus listed overhang

As of August 11, 2026, Cardiol reported 116.82 million issued common shares. The following maximum-equivalent bridge is a risk map, not a forecast of conversion or a treasury-stock-method diluted count.

Warrants and options may never be exercised and, if exercised, can bring in cash. RSUs, PSUs and contingent shares have vesting or performance conditions. Conversely, clinical success would still leave NDA, manufacturing and launch costs, so additional capital before commercialization remains a realistic scenario.

Primary sources: Q2 financial statements, Q2 MD&A and Q1 statements used for the Q2 cash-use derivation.

15 Valuation framework: the inputs, and what they do not settle

The SEC-based equity value is deliberately separated from the Finviz enterprise value and the Canadian-dollar cash balance. Mixing a U.S. share price, a different-date share count and an unstated FX conversion can create false precision. The most defensible conclusion is qualitative: most value above cash is tied to CardiolRx in recurrent pericarditis, because ARCHER has no disclosed pivotal plan and CRD-38 has no human data.

Why a conventional target price would be false precision

A responsible rNPV needs probabilities for Phase III success, NDA acceptance and approval; assumptions for label, launch, price, gross-to-net, duration, penetration and commercial spending; a discount rate; and a realistic future share count. Small changes can move value several-fold. Merlintrader therefore does not publish a proprietary CRDL target.

Finviz’s third-party analyst aggregate was US$7.30 at August 17, 2026. That is an opinion summary, not company guidance, a floor or a Merlintrader forecast. Historical individual targets should not be treated as current unless the underlying report and assumptions are available.

Threshold questions for any model

• Does it value only the post-IL-1 population tested in MAVERIC, or assume broader use without evidence?
• Does it include a financing before commercial launch and use an appropriately diluted denominator?
• Does it benchmark efficacy, convenience and price against ARCALYST without assuming equal labels?
• Does it heavily discount CRD-38 until human PK and safety exist?
• Does the downside case use the cash balance after the readout rather than the June balance?

Market-data source: Finviz snapshot, August 12, 2026. Financial and share-count source: Q2 MD&A.

16 Catalyst map: confirmed events, guided windows and conditional milestones

10 September 2026 update: Cardiol filed a preliminary base shelf prospectus and a corresponding Form F-10 on September 10. Subject to the final prospectus receipt and U.S. effectiveness, it would allow up to US$150 million of securities over 25 months. No securities are being offered with this announcement. The company also expanded program-cost and expense disclosures following an OSC staff review. Sources and implications.

For live monitoring, use the Merlintrader Biotech Catalyst Calendar and recheck guidance against fresh filings and ClinicalTrials.gov.

September 9, 2026 — H.C. Wainwright fireside chat on September 14

Cardiol announced a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 10:30 a.m. EDT. A live webcast will be available through the company’s Events & Presentations page. This is an investor event, not an announced clinical readout or confirmation that MAVERIC enrollment is complete.

Company release

17 Risk register and thesis falsifiers

10 September 2026 update: Cardiol filed a preliminary base shelf prospectus and a corresponding Form F-10 on September 10. Subject to the final prospectus receipt and U.S. effectiveness, it would allow up to US$150 million of securities over 25 months. No securities are being offered with this announcement. The company also expanded program-cost and expense disclosures following an OSC staff review. Sources and implications.

The central falsifier is simple: CardiolRx fails to prevent recurrent pericarditis after IL-1 withdrawal with a clinically persuasive effect and acceptable safety. Biomarker or imaging improvement would not repair a failed recurrence endpoint.

18 Bull, middle and bear scenarios—without pretending to know the result

Bull case

Enrollment completes within Q3, Q1 2027 guidance holds, MAVERIC reports a large and statistically robust recurrence benefit, secondary measures align and safety supports chronic use. FDA confirms a workable filing path, the oral post-IL-1 position is credible and partnership or financing occurs from greater leverage.

Middle case

The primary endpoint is positive but the effect is moderate, the confidence interval is wide, subgroups diverge or safety and duration raise questions. An NDA may remain possible, but label breadth and differentiation are debated. Detailed data and FDA feedback, rather than the headline, determine value.

Bear case

MAVERIC misses or produces an inconclusive clinical effect, or tolerability changes the benefit-risk balance. Pericarditis loses most near-term registration value; ARCHER remains non-pivotal; CRD-38 is too early to carry valuation; and cash plus dilution dominate the story.

What the numbers above do and do not measure

At roughly US$251.2 million of SEC-based basic equity value at the September 1, 2026 close and a Finviz enterprise-value estimate of US$156.4 million, CRDL trades above residual cash and preclinical optionality. The market therefore assigns some probability-weighted value to MAVERIC while retaining a large discount for clinical, regulatory, commercial and financing risk.

What can change the setup before the readout?

• Formal enrollment completion with the Q1 2027 window maintained.
• More detailed peer-reviewed or congress discussion that clarifies dose, safety and recurrence definitions.
• CRD-38 IND-enabling progress or a funded partnership, without implying human efficacy.
• A financing that extends post-readout flexibility on acceptable terms—or, negatively, a discounted deal that expands overhang.

19 Bottom line

10 September 2026 update: Cardiol filed a preliminary base shelf prospectus and a corresponding Form F-10 on September 10. Subject to the final prospectus receipt and U.S. effectiveness, it would allow up to US$150 million of securities over 25 months. No securities are being offered with this announcement. The company also expanded program-cost and expense disclosures following an OSC staff review. Sources and implications.

Cardiol has a legitimate late-stage catalyst in a clinically relevant and commercially validated disease. CardiolRx offers a potentially convenient oral, non-immunosuppressive profile; the Phase II signal is coherent and peer reviewed; the pivotal study is advanced; and the Q2 filing adds a defined end-Q3 enrollment target plus stated funding into Q4 2027.

The limits remain decisive. The pericarditis pilot was small and uncontrolled. ARCHER missed both co-primary endpoints. CRD-38 is not in humans. The company is pre-revenue, has 20.07 million listed potential share equivalents above the August basic count and will likely need more capital before commercialization even if MAVERIC succeeds.

The one question that matters most: can CardiolRx keep high-risk patients free from recurrent pericarditis for 24 weeks after withdrawal of IL-1 blockade, with an effect large and safe enough for regulators, physicians and payers? Until randomized Phase III data answer that, CRDL remains evidence-backed but binary biotech research—not certainty and not an implicit recommendation.

20 Primary-source library

• August 12, 2026 Form 6-K
• Q2 2026 condensed interim financial statements
• Q2 2026 Management’s Discussion and Analysis
• Q1 2026 statements used for the derived Q2 cash-use calculation
• July 2026 corporate presentation
• MAVERIC Phase III — ClinicalTrials.gov
• MAvERIC-Pilot Phase II — ClinicalTrials.gov
• MAvERIC-Pilot peer-reviewed JAHA article
• ARCHER Phase II — ClinicalTrials.gov
• ARCHER peer-reviewed ESC Heart Failure article
• Cardiol company pipeline
• Finviz market-data snapshot

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

21 Follow the next CRDL catalyst

For biotech-catalyst updates, SEC and trial-record checks, and new Merlintrader research, join the Telegram channel and use the live calendar. Recheck company guidance at the source because enrollment and readout windows can change.

Join @merlintraderpub_com · Open the Catalyst Calendar · RunUP Biotech Masterclass

Risk disclosure. This Stock Hub is independent educational and informational content. It is not investment research, personalized financial advice, a recommendation, an offer or a solicitation to buy, sell or hold securities. CRDL is a speculative, pre-revenue biotech exposed to clinical, regulatory, manufacturing, financing, dilution, liquidity and binary-event risk, including partial or total loss of capital. Company statements about timelines, market opportunities, regulatory paths, cash runway and future results are forward looking and may prove wrong.

Data cut-off: September 2, 2026. Market data use the September 1, 2026 Nasdaq close from Marketstack and the August 17, 2026 Finviz snapshot. Financial statements are as of June 30, 2026; security counts are updated through the August 11 Q2 MD&A. Clinical and corporate developments were checked through September 2, 2026.